The cancer therapeutic drugs market is projected to grow at a CAGR of 6.87% to reach US$223.141 billion by 2024 from US$149.750 billion in 2018. The cancer therapeutic drugs market is expected to grow at a fast pace during the forecast period due to the growing incidence of cancers worldwide. Geographically, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions, in addition to having a high cancer prevalence in the country. The growing adoption of unhealthy living conditions is further emanating the market growth during the forecast period. Furthermore, growing cancer drug spending is driving the growth of the global cancer therapeutics market during the forecast period. The growing number of clinical trials have improved the chances of new innovations for targeted cancer treatment, emanating the market growth during the forecast period and beyond. Growing health awareness among people worldwide will lead to early diagnosis, further leading to the treatment of cancer, when detected at an early stage, thus, propelling the market growth in the forecast period.
DRIVERS
Rising cancer incidences worldwide
Growing cancer drug spending
Increasing health awareness among people worldwide
RESTRAINTS
The high cost of cancer treatment
INDUSTRY UPDATE
On 17th June 2019, Pfizer announced that it has entered into a definitive merger agreement under which it will acquire Array Pharma.
On 31st August 2018, Servier Pharmaceuticals announced that it has completed the acquisition of Shire’s oncology business.
Major industry players profiled as part of the report are Pfizer Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Janssen Global Services, LLC, Eli Lilly and Company, Merck & Co., Inc., and Astellas Pharma Inc.
| Report Metric | Details |
| Market size value in 2018 | US$149.750 billion |
| Market size value in 2024 | US$223.141 billion |
| Growth Rate | CAGR of 6.87% from 2018 to 2024 |
| Base year | 2018 |
| Forecast period | 2019–2024 |
| Forecast Unit (Value) | USD Billion |
| Segments covered | Indication, Product Type, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Pfizer Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Janssen Global Services, LLC, Eli Lilly and Company, Merck & Co., Inc., Astellas Pharma Inc. |
| Customization scope | Free report customization with purchase |
Segmentation
The cancer therapeutic drugs market has been analyzed through the following segments:
By Indication
Skin Cancer
Lung Cancer
Breast Cancer
Prostate Cancer
Others
By Product Type
Revlimid
Avastin
Herceptin
Rituxan
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Others
Frequently Asked Questions (FAQs)
Q1. What will be the cancer therapeutic drugs market size by 2024?
A1. The cancer therapeutic drugs market is projected to reach a total market size of US$223.141 billion in 2024.
Q2. What are the growth prospects for the cancer therapeutic drugs market?
A2. The global cancer therapeutics drugs market is projected to grow at a CAGR of 6.87% over the forecast period.
Q3. What is the size of the global cancer therapeutics drugs market?
A3. Cancer Therapeutic Drugs Market was valued at US$149.750 billion in 2018.
Q4. Which region holds the largest market share in the cancer therapeutic drugs market?
A4. Geographically, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions, in addition to having a high cancer prevalence in the country.
Q5. What factors are anticipated to drive the cancer therapeutic drugs market growth?
A5. The growing adoption of unhealthy living conditions is further emanating the cancer therapeutic drugs market growth during the forecast period.
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By region
4.6. Product Pipeline
4.7. Innovations
5. CANCER THERAPEUTIC DRUGS MARKET BY INDICATION
5.1. Skin Cancer
5.2. Lung Cancer
5.3. Breast Cancer
5.4. Prostate Cancer
5.5. Others
6. CANCER THERAPEUTIC DRUGS MARKET BY PRODUCT TYPE
6.1. Revlimid
6.2. Avastin
6.3. Herceptin
6.4. Rituxan
6.5. Others
7. CANCER THERAPEUTIC DRUGS MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Pfizer Inc.
9.2. Celgene Corporation
9.3. F. Hoffmann-La Roche Ltd
9.4. Bristol-Myers Squibb Company
9.5. Novartis Pharmaceuticals Corporation
9.6. Janssen Global Services, LLC
9.7. Eli Lilly and Company
9.8. Merck & Co., Inc.
9.9. Astellas Pharma Inc.
LIST OF FIGURES
LIST OF TABLES
Pfizer Inc.
Celgene Corporation
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
Novartis Pharmaceuticals Corporation
Janssen Global Services, LLC
Eli Lilly and Company
Merck & Co., Inc.
Astellas Pharma Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.